Navigation Links
HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
Date:3/16/2012

FRAMINGHAM, Mass. and SYDNEY, March 16, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a fourth allotment, of 54 additional patients, in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).  In three prior CAP allotments granted by FDA, 202 patients were enrolled between April 2010 and December 2011.

HeartWare's ADVANCE clinical trial is an FDA approved IDE study designed to evaluate the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure.  Under the ADVANCE study, 140 patients at 30 U.S. clinical sites received HeartWare HVAD® pumps, making it the largest bridge-to-transplant pivotal trial to date.  HeartWare submitted to the FDA a Pre-Market Approval (PMA) application seeking approval of the HeartWare System for the bridge-to-transplant indication in December 2010, and an FDA Circulatory System Devices Panel will review the PMA application on April 25, 2012.

Patient enrollment under the new CAP can now commence at the 30 centers participating in the ADVANCE clinical trial, subject to Institutional Review Board approvals at those sites. 

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  The HeartWare System has received CE Marking in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical trials, expected timing of regulatory filings and approvals, and research and development activities.  Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility the FDA does not approve the marketing of the HeartWare® Ventricular Assist System in the U.S., and those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

 


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Governor Andrew M. Cuomo today announced ... jobs throughout Western New York . ... SUNY Polytechnic Institute, includes a major expansion of Athenex,s ... Buffalo , as well as the creation ... Dunkirk . The combined projects are ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
(Date:2/11/2016)... -- Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or ... go, ALEX is said to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... industry, ranked among the top five firms in the “2015/2016 Best in KLAS: ... Support and Staffing. KLAS is a research and insights firm on a global ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... ... ... In a new paper published in the latest issue ... Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage in ... this vital area. , The upper lateral cartilage in rhinoplasty, refers to a ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... decision support technology, with highly adaptable algorithms, has been updated to help Emergency ... signs and symptoms consistent with Zikas and a travel history to affected regions, ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you back ... Clarke poses a question as a challenge for his readers to examine the ... the Being" (published by Partridge Singapore), Clarke explores the subject with more depth, ...
Breaking Medicine News(10 mins):